Shares of Radius Health, Inc. (NASDAQ:RDUS) have earned a consensus recommendation of “Hold” from the ten analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $53.60.

A number of research firms have weighed in on RDUS. Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the stock a “buy” rating in a research note on Monday, July 17th. ValuEngine raised shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Cantor Fitzgerald set a $58.00 price objective on shares of Radius Health and gave the stock a “buy” rating in a research report on Sunday, July 23rd. BidaskClub lowered shares of Radius Health from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $38.00 price objective (up previously from $34.00) on shares of Radius Health in a research report on Wednesday, August 9th.

WARNING: “Radius Health, Inc. (RDUS) Given Consensus Recommendation of “Hold” by Analysts” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/16/radius-health-inc-rdus-given-consensus-recommendation-of-hold-by-analysts.html.

Radius Health (NASDAQ:RDUS) traded up 1.67% during mid-day trading on Friday, reaching $33.54. 2,925,848 shares of the company traded hands. Radius Health has a 52-week low of $31.58 and a 52-week high of $59.22. The stock’s market capitalization is $1.46 billion. The stock has a 50-day moving average of $37.32 and a 200 day moving average of $39.12.

Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.23). The business had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.96 million. During the same quarter in the prior year, the company posted ($1.01) earnings per share. Equities research analysts expect that Radius Health will post ($5.58) earnings per share for the current year.

In other Radius Health news, major shareholder Growth N. V. Biotech acquired 150,000 shares of the company’s stock in a transaction dated Thursday, August 10th. The stock was bought at an average price of $34.97 per share, with a total value of $5,245,500.00. Following the completion of the transaction, the insider now directly owns 5,113,799 shares of the company’s stock, valued at $178,829,551.03. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was acquired at an average cost of $36.75 per share, with a total value of $1,837,500.00. Following the transaction, the insider now directly owns 5,298,799 shares of the company’s stock, valued at $194,730,863.25. The disclosure for this purchase can be found here. Insiders bought 469,100 shares of company stock valued at $16,328,382 in the last three months. Company insiders own 15.00% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RDUS. BlackRock Inc. grew its holdings in Radius Health by 98,245.6% during the 1st quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after purchasing an additional 2,628,070 shares in the last quarter. Farallon Capital Management LLC grew its holdings in Radius Health by 18.3% during the 2nd quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after purchasing an additional 569,300 shares in the last quarter. TimesSquare Capital Management LLC acquired a new stake in Radius Health during the 2nd quarter valued at $25,589,000. BB Biotech AG grew its holdings in Radius Health by 11.0% during the 2nd quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after purchasing an additional 498,400 shares in the last quarter. Finally, RA Capital Management LLC acquired a new stake in Radius Health during the 2nd quarter valued at $22,486,000.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.